Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”) released its Monthly Return for the period ended 31 July 2026, detailing a focused on-market share repurchase programme and confirming compliance with public-float requirements.

Authorised Share Capital • No change was recorded during the month. Authorised H-shares remained at 4.52 billion with a par value of RMB 0.10 each, while authorised non-listed shares stayed at 48.30 million. Total authorised share capital thus held steady at RMB 457.06 million.

Issued and Treasury Shares • Issued H-shares (excluding treasury shares) fell by 2.43 million to 4,459.84 million as of 31 July 2026. • Treasury stock increased by the same 2.43 million shares to 62.49 million, equivalent to approximately 1.38% of the company’s total issued share base. • The net reduction in outstanding H-shares represents about 0.05% of total issued shares.

Repurchase Activity • Twelve on-market buybacks were executed between 2 July and 22 July 2026 at prices ranging from HK$3.18 to HK$3.44 per share. • Total consideration amounted to roughly HK$7.95 million, implying an average repurchase price of HK$3.27 per share. • All repurchased shares are being held in treasury; no cancellations were reported for the period.

Capital Instruments • The company reported no movements in share options, warrants, convertibles, or other agreements to issue new shares during the month.

Public Float • Management affirmed that the public-float ratio remained above the Main Board’s 25% minimum threshold at month-end, despite the reduction in free-float shares from the buyback.

Compliance Statement • The company secretary confirmed that all repurchase activities were duly authorised by the Board and executed in accordance with applicable listing rules and regulations.